Tilray Brands (TLRY) Gains from Investment Securities (2019 - 2025)
Tilray Brands (TLRY) posted Gains from Investment Securities of -$15.0 million for Q3 2025, down 1600.0% on a QoQ basis from $1.0 million in Q2 2024.
Tilray Brands (TLRY) Gains from Investment Securities (2019 - 2025) Analysis & Trends
Tilray Brands' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at -$15.0 million for Q3 2025.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$15.0 million in Q3 2025, while the trailing twelve-month figure through Feb 2026 was -$15.0 million (down 1600.0% YoY) and the FY2024 annual result came in at -$15.8 million, down 1946.78% from the prior year.
- Gains from Investment Securities was -$15.0 million for Q3 2025 at Tilray Brands, down from $1.0 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.0 million in Q2 2024 and bottomed at -$30.7 million in Q1 2022.
- A 5-year average of -$6.2 million and a median of $251500.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 5363.98% — and 2024, when it jumped 242.47%.
- Tilray Brands' Gains from Investment Securities stood at $845000.0 in 2021, then tumbled by 75.03% to $211000.0 in 2022, then soared by 42.18% to $300000.0 in 2023, then surged by 233.33% to $1.0 million in 2024, then tumbled by 1600.0% to -$15.0 million in 2025.
- Business Quant data shows TLRY's Gains from Investment Securities at -$15.0 million in Q3 2025, $1.0 million in Q2 2024, and -$6.0 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.02 Bn | 32.28 Bn | 1.97 Bn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.94 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.35 Bn | 18.54 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Tilray Brands | 450.71 Mn | 390.52 Mn | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | -15.00 Mn |
| Aug 31, 2025 | -15.00 Mn |
| May 31, 2024 | 1.00 Mn |
| May 31, 2024 | 1.00 Mn |
| Feb 29, 2024 | -5.98 Mn |
| Feb 29, 2024 | -5.98 Mn |
| Nov 30, 2023 | 300,000.00 |
| Nov 30, 2023 | 300,000.00 |
| Aug 31, 2023 | -11.11 Mn |
| Aug 31, 2023 | -11.11 Mn |
| May 31, 2023 | 292,000.00 |
| May 31, 2023 | 292,000.00 |
| Feb 28, 2023 | 352,000.00 |
| Feb 28, 2023 | 352,000.00 |
| Aug 31, 2022 | 211,000.00 |
| Aug 31, 2022 | 211,000.00 |
| May 31, 2022 | -15.59 Mn |
| May 31, 2022 | -15.59 Mn |
| Feb 28, 2022 | -30.75 Mn |
| Feb 28, 2022 | -30.75 Mn |